Castle Biosciences opened lower at $33.64, compared with its previous close of $33.99. In the last trading session, the stock traded between $32.76 and $34.68. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Castle Biosciences is now worth
$ 65.32
Resulting in a loss of
$ 34.68 (34.68%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.50 (+1.47%)
Day High
$34.68
Day Low
$32.76
Day Open
$33.64
Prev Close
$33.99
Volume
3,21,423
1W Return
-3.59%
1M Return
5.09%
3M Return
6.96%
6M Return
81.14%
1Y Return
-1.37%
Fundamentals
Market Cap ($ Mn)
1,063
PE Ratio
-
PB Ratio
2.17
PEG Ratio
-
ROE
-5.28%
ROCE
-8.38%
EPS (TTM)
$-0.13
Investment Returns
1 Week
-3.59%
1 Month
5.09%
3 Months
6.96%
6 Months
81.14%
9 Months
6.65%
Financials
Quarterly
All values in $ Mn
86.2
Jun 25
83.0
Sep 25
87.0
Dec 25
83.7
Mar 26
103.5
Jun 26
102.9
Sep 26
Updates
9Nov
Baird maintains Outperform on Castle Biosciences, lifts target to $41
Baird maintains Outperform rating on Castle Biosciences. Price target raised from $39 to $41. Analyst Catherine Ramsey authored the rating update.
3 days ago
6Nov
Keybanc maintains Overweight on Castle Biosciences, hikes target to $40
Keybanc maintains Overweight rating on Castle Biosciences. Price target increased from $35 to $40 by analyst Paul Knight. No change in investment stance despite higher target.
6 days ago
6Nov
Castle Biosciences Q3FY26 Results: Revenue rises 24% to $102.9 million
Revenue reached $102.9 million in Q3 FY26, up 24% YoY. TissueCypher test volume grew 47% YoY to 15,574 reports. Adjusted EBITDA improved to $12.7 million from $9.2 million. Full-year 2026 revenue guidance raised to $385-$395 million.
7 days ago
1Oct
Castle Biosciences to present melanoma test data at EADV 2026
Castle Biosciences presents data from a 2,799-patient study on DecisionDx-Melanoma at EADV 2026. Low-risk patients avoiding SLNB achieved 99.6% five-year recurrence-free survival. High-risk group showed 22.8% observed sentinel lymph node positivity versus 4.4% in low-risk. Early-stage patients with high-risk Class 2B results had 73.7% five-year RFS, similar to stage IIB.
1mo ago
25Sep
Study shows 94% of atopic dermatitis patients seek molecular guidance
94% of AD patients open to new systemic therapies want molecular testing. 55% of patients using targeted therapies modified treatment due to lack of efficacy. AdvanceAD-Tx users with JAK responder profile were 5.5 times more likely to reach EASI-90. Study involved 43 patients and caregivers at 2024 National Eczema Association Expo.
1mo ago
22Sep
Castle Biosciences opens new 55,000 sq ft facility in Scottsdale
Castle Biosciences opens a new 55,000-square-foot laboratory and office in Scottsdale, Arizona. The expansion supports growing test volumes and long-term operational growth. A grand opening celebration is scheduled for October 6, 2026, at 3:30 pm MST.
